AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

The American Geriatrics Society has published a case-based framework to help clinicians prescribe obesity medications, including GLP-1 therapies, to older adults. It recommends assessing function, nutrition and cognition before treatment, and considering measures such as resistance training and adequate protein intake alongside medication.

The American Geriatrics Society (AGS) has published a case-based framework for clinicians prescribing obesity medications to older adults, addressing how to weigh potential benefits against age-related risks. The paper applies the AGS Geriatrics 5Ms—Mind, Mobility, Medications, Multicomplexity and Matters Most—to treatment decisions, including for GLP-1 medicines.

Before you orderOffer from Amazon

Get workout gear delivered free with Prime

  • Fast, free delivery on millions of items
  • Prime Video, Amazon Music and more included
  • Member-only deals all year
Start your free Prime trial Free trial for eligible customers · Cancel anytime
As an affiliate, we earn on qualifying purchases.

The framework was developed by the AGS Healthy Aging Special Interest Group and published in the Journal of the American Geriatrics Society. Its case-based format is intended to help clinicians apply geriatric considerations to prescribing decisions, rather than treating medication choice as separate from a patient’s overall health and priorities.

Before starting treatment, the authors recommend evaluating functional status, nutritional adequacy and cognitive impairment. They also call attention to concerns that may be especially relevant in later life, including frailty, sarcopenia, lean muscle loss, malnutrition and dehydration. The source report does not provide a single prescribing rule or say that these risks apply equally to every patient.

The paper recommends pairing medication with supportive measures such as resistance training and adequate dietary protein. For some older adults, care may involve a team that includes a registered dietitian, physical therapist, fitness trainer and behavioral health professional. The article describes these as considerations for individualized care, not as a requirement for every person taking an obesity medication.

At a glance
reportWhen: Published October 2026
The developmentThe American Geriatrics Society has published a clinical framework applying its Geriatrics 5Ms approach to obesity medication prescribing in older adults.

Balancing Weight Treatment With Healthy Aging

The framework addresses a gap between growing use of obesity medicines and the evidence available for older patients. According to the source report, older adults are underrepresented in clinical trials. That makes it harder to assume that findings from broader adult populations fully capture how treatment interacts with age-related changes in strength, nutrition, mobility and other health conditions.

For patients and clinicians, the practical point is that a medication decision should account for more than weight or blood sugar alone. Assessing mobility, muscle and nutritional status can help clinicians consider possible trade-offs and supportive care when discussing treatment. The framework also puts individual priorities into the decision through the “Matters Most” element of the 5Ms.

The paper does not establish that obesity medicines are unsafe for older adults, nor does it report new trial results showing a particular benefit or harm. Rather, it offers a structured approach to clinical judgment in a population for which the report says trial representation is limited.

Products Worth Considering

As an affiliate, we earn on qualifying purchases.

How the Geriatrics 5Ms Apply

The AGS Geriatrics 5Ms are a framework for organizing care around Mind, Mobility, Medications, Multicomplexity and Matters Most. In this paper, the authors use those categories to consider incretin-based treatment, a group that includes GLP-1 medications acting through gut-derived hormonal pathways.

The report says these medicines may offer benefits for weight management, glycemic control and other health conditions. Those are described as promising benefits, not as guaranteed outcomes for every older patient. The framework’s emphasis is on assessing the person’s overall circumstances before prescribing and considering complementary supports during care.

The article is based on a paper by Elias M. Wisdom and co-authors, titled “Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing.” It appeared in the Journal of the American Geriatrics Society in 2026 (DOI: 10.1111/jgs.70769). The source material describes a clinical framework, not a clinical trial or a new medication approval.

“Safe prescribing requires pretreatment assessment of functional status, nutritional adequacy and cognitive impairment.”

— The paper’s authors, as summarized in the Medical Xpress report

Evidence Gaps and Individual Risks

The source report does not give trial results, quantify medication-related risks in older adults or compare specific drugs. It also does not specify which patients should or should not receive treatment, or provide a dosing protocol. The framework therefore should not be read as a blanket recommendation or as a substitute for decisions made with a clinician familiar with the patient’s health.

How the medicines affect outcomes such as muscle strength, nutritional status and function across different groups of older adults remains an evidence question. The report says older adults are underrepresented in clinical trials, but does not give the size of that gap or identify particular age groups, health conditions or medications with stronger evidence. The best approach for an individual patient will depend on factors assessed in clinical care.

Putting the Framework Into Practice

The paper provides clinicians with a case-based method for considering obesity medication use through geriatric priorities. The next step described by the report is its application in practice: clinicians can use the 5Ms to organize pretreatment assessment, discuss goals that matter to the patient and consider whether nutrition, exercise or team-based support should accompany medication.

The source material does not announce a follow-up study, implementation timeline or formal update to prescribing rules. Further evidence on older adults’ outcomes would help clarify how benefits and risks vary across patients. For now, the framework is a clinical decision aid; treatment choices remain individualized and should be discussed with a qualified healthcare professional.

Key Questions

What did the American Geriatrics Society publish?

The AGS published a case-based framework to help clinicians consider obesity medication prescribing in older adults using its Geriatrics 5Ms approach.

Does the framework recommend obesity medication for every older adult?

No. The source describes a method for individualized prescribing decisions, not a recommendation that all older adults use these medicines.

What should clinicians assess before treatment?

The authors recommend considering functional status, nutritional adequacy and cognitive impairment, as well as age-related concerns including frailty, muscle loss, malnutrition and dehydration.

What other support may be considered with medication?

The paper recommends considering resistance training and adequate dietary protein. Some patients may benefit from a team approach involving professionals such as a dietitian or physical therapist.

Does the report provide new evidence that these medicines are safe or effective in older adults?

No new clinical trial findings are reported. The paper offers a prescribing framework; the source says older adults are underrepresented in trials and does not quantify treatment outcomes or risks.

Source: medicalxpress.com

Wellness content on this site is informational and not a substitute for professional medical guidance.
You May Also Like

PSA: Public Health Alert Issued For Raw Chicken Breast Sold At Stores In Nine States

A public health alert has been issued for raw chicken breast sold in stores across nine states due to contamination concerns. Details inside.

Fentanyl

Search interest in fentanyl has surged, driven by increased media coverage and public awareness, though specific events remain unconfirmed.

Low-Dose Naltrexone Linked To Some Long COVID Improvements

A 230-person Stanford clinic study found reported symptom and functioning improvements, but its uncontrolled design cannot show that naltrexone caused them.

Cv Sciences Surges In Global Coverage

Coverage of Cv Sciences has surged globally, with 27 mentions in recent reports, signaling increased media interest amid ongoing developments.